Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Commissioner Margaret Hamburg says Genentech has failed to identify a subpopulation of patients in whom the clinical benefits outweigh the risks. The company says it will not appeal the indication’s withdrawal but will pursue a new study in breast cancer.
You may also be interested in...
Accelerated Approval: Former ODAC Member Sekeres Reflects On Avastin Withdrawal
Leukemia specialist Mikkael Sekeres’ new book, “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust,” serves two purposes: a history of FDA oversight and regulation of drugs, as shaped by various public health crises and tragedies; and an insider's account of the June 2011 hearing on withdrawal of Avastin’s accelerated approval in breast cancer.
AMAG Open To Another Makena Trial, But Also Appears Ready To Challenge Any Withdrawal Request
CEO William Heiden reaffirms commitment to preterm birth drug and suggests AMAG would seek a hearing under the accelerated approval regulations if the US FDA were to request withdrawal; another placebo-controlled confirmatory trial may be possible in European and South American countries, company says.
Makena’s Accelerated Approval Will Hang In Balance At US FDA Panel Meeting In October
Advisory committee will re-evaluate the continued marketing of AMAG Pharmaceuticals’ preterm birth drug after a failed confirmatory study; the last time an advisory committee weighed in on the future of an accelerated approval drug was for Avastin's breast cancer claim.